Trevi Therapeutics (TRVI) Other financing activities (2018 - 2026)

Trevi Therapeutics' Other financing activities history runs 9 years deep, the most recent figure standing at $222000.0 for Q1 2026.

• On a quarterly basis, Other financing activities fell 69.08% year-over-year to $222000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 42.87% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, up 427.66% from the prior year.
• Other financing activities advanced to $222000.0 in Q1 2026 per TRVI's latest filing, from -$8.7 million in the prior quarter.
• Across five years, Other financing activities topped out at $10.0 million in Q2 2025 and bottomed at -$8.7 million in Q4 2025.
• The 5-year median for Other financing activities is $41000.0 (2023), against an average of $193866.7.
• Biggest YoY gain for Other financing activities was 33363.33% in 2025; the steepest drop was 66853.85% in 2025.
• Year by year, Other financing activities stood at $116000.0 in 2022, then slumped by 64.66% to $41000.0 in 2023, then tumbled by 68.29% to $13000.0 in 2024, then sank by 66853.85% to -$8.7 million in 2025, then soared by 102.56% to $222000.0 in 2026.
• Per Business Quant, the three latest TRVI Other financing activities figures stand at $222000.0 (Q1 2026), -$8.7 million (Q4 2025), and $10.0 million (Q2 2025).